Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share
Equities research analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.55) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The firm is scheduled to report its next quarterly earnings results on Friday, March 9th.
On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($2.82) per share for the current fiscal year, with EPS estimates ranging from ($2.84) to ($2.80). For the next year, analysts forecast that the firm will report earnings of ($3.23) per share, with EPS estimates ranging from ($3.28) to ($3.18). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19.
Shares of Corvus Pharmaceuticals (NASDAQ CRVS) traded down $0.31 during trading hours on Thursday, reaching $10.69. 49,600 shares of the company’s stock were exchanged, compared to its average volume of 106,371. Corvus Pharmaceuticals has a 12-month low of $8.27 and a 12-month high of $22.14.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller bought 10,000 shares of Corvus Pharmaceuticals stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 46.40% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC raised its position in shares of Corvus Pharmaceuticals by 87.4% in the 2nd quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock valued at $12,330,000 after acquiring an additional 475,164 shares during the period. EcoR1 Capital LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $9,741,000. Vanguard Group Inc. raised its position in shares of Corvus Pharmaceuticals by 37.1% in the 2nd quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after acquiring an additional 101,013 shares during the period. JPMorgan Chase & Co. raised its position in shares of Corvus Pharmaceuticals by 116.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock valued at $4,025,000 after acquiring an additional 178,658 shares during the period. Finally, Northern Trust Corp raised its position in shares of Corvus Pharmaceuticals by 97.6% in the 2nd quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock valued at $1,047,000 after acquiring an additional 42,739 shares during the period. 83.47% of the stock is currently owned by institutional investors.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.